Recombinant mouse IL-27-A protein (Animal Free) (ab187220)
Key features and details
- Expression system: Escherichia coli
- Purity: >= 97% SDS-PAGE
- Endotoxin level: <= 1.000 Eu/µg
- Active: Yes
- Suitable for: Functional Studies, SDS-PAGE
製品の詳細
-
製品名
Recombinant mouse IL-27-A protein (Animal Free)
IL-27-A タンパク質・ペプチド 製品一覧 -
生理活性
The activity is measured via dose-dependent inhibition of IL17A expression from mouse CD4+ splenocytes stimulated with TGF-β and IL6. 50ng/mL typically inhibits greater than 25% of IL17A expression.
-
精製度
>= 97 % SDS-PAGE.
Determined by reducing and Non-reducing SDS-PAGE -
エンドトキシン・レベル
<=1.000 Eu/µg -
発現系
Escherichia coli -
アクセッション番号
-
タンパク質長
Full length protein -
Animal free
Yes -
由来
Recombinant -
-
生物種
Mouse -
配列
MFPTDPLSLQELRREFTVSLYLARKLLSEVQGYVHSFAESRLPGVNLDLL PLGYHLPNVSLTFQAWHHLSDSERLCFLATTLRPFPAMLGGLGTQGTWTS SEREQLWAMRLDLRDLHRHLRFQVLAAGFKCSKEEEDKEEEEEEEEEEKK LPLGALGGPNQVSSQVSWPQLLYTYQLLHSLELVLSRAVRDLLLLSLPRR PGSAWDS -
予測される分子量
24 kDa -
領域
29 to 234
-
特性
Our Abpromise guarantee covers the use of ab187220 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
アプリケーション
Functional Studies
SDS-PAGE
-
製品の状態
Lyophilized -
Concentration information loading...
前処理および保存
-
保存方法および安定性
Shipped at 4°C. Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. For long term storage it is recommended to add a carrier protein on reconstitution (0.1% HSA or BSA).
Constituent: 0.14% Sodium phosphate
This product is an active protein and may elicit a biological response in vivo, handle with caution.
-
再構成Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile water at a concentration of 0.1 mg/mL, which can be further diluted into other aqueous solutions.
関連情報
-
別名
- EBI3
- IL 27
- IL 27 p28 subunit
see all -
機能
Cytokine with pro- and anti-inflammatory properties, that can regulate T helper cell development, suppress T-cell proliferation, stimulate cytotoxic T cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL-27 subunit p28 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replivation. -
組織特異性
Expressed in monocytes and in placenta. -
配列類似性
Belongs to the IL-6 superfamily. -
翻訳後修飾
O-glycosylated. -
細胞内局在
Secreted. Does not seem to be secreted without coexpression of EBI3. - Information by UniProt
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
Datasheet download
参考文献 (0)
ab187220 は論文での使用が確認できていません。